Sun Pharmaceutical Industries
SUNPHARMA · Pharma · NSE
₹1,680
Current Market Price
Fair Value (DCF)
₹1,350
Margin of Safety
-19.7%
Updated 5h ago
YieldIQ Score
28/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
35%
ROE
15.1%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹4.03 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.9%
Return on capital employed
EV / EBITDA
23.0×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
60.4×
EBIT covers interest
Current Ratio
2.89×
Short-term liquidity
Asset Turnover
0.60×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
34.1%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,680.1
Bear case
₹812.46
MoS -106.8%
Base case
₹1,349.88
MoS -24.5%
Bull case
₹1,834.87
MoS +8.4%
Ratio Trends
SUNPHARMA · last 8 annual periods
ROE
15.1%
ROCE
22.1%
Operating Margin
—
Debt / Equity
0.03×
PE
38.1×
EV / EBITDA
24.7×
Historical Financials
SUNPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹12.8K Cr | ₹38.7K Cr | ₹10.9K Cr | ₹12.0K Cr | ₹52.0K Cr | +42.0% |
| EBITDA | — | ₹6752 Cr | ₹12.1K Cr | ₹13.9K Cr | ₹16.6K Cr | +25.1% |
| EBIT | ₹2410 Cr | ₹4609 Cr | ₹2332 Cr | ₹2889 Cr | — | +4.6% |
| PAT | ₹2140 Cr | ₹3389 Cr | ₹1983 Cr | ₹2659 Cr | ₹10.9K Cr | +50.3% |
| EPS (diluted) | ₹8.92 | ₹13.60 | ₹8.30 | ₹11.10 | — | +5.6% |
| CFO | ₹1737 Cr | ₹8985 Cr | ₹4959 Cr | ₹12.1K Cr | ₹14.1K Cr | +68.7% |
| CapEx | — | — | — | — | ₹-2129 Cr | — |
| FCF | — | — | — | — | ₹11.9K Cr | +0.0% |
| Total Assets | — | ₹69.8K Cr | ₹80.7K Cr | ₹85.5K Cr | ₹92.1K Cr | +7.2% |
| Total Debt | — | — | ₹6198 Cr | ₹2844 Cr | ₹2362 Cr | -21.4% |
| Shareholders' Equity | — | — | ₹56.0K Cr | ₹63.7K Cr | ₹72.5K Cr | +6.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SUNPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| DIVISLAB DIVISLAB | — | — | Pending | 14.6% | 0.8× |
| TORNTPHARM TORNTPHARM | — | — | Pending | 25.2% | — |
| LUPIN Lupin Limited | +16.1% | 37 | Undervalued | 19.0% | — |
| DRREDDY Dr. Reddy's Laboratories Limited | +73.3% | 63 | Undervalued | 16.8% | 16.8× |
| CIPLA Cipla Limited | +43.1% | 66 | Data Limited | 16.9% | 22.1× |
Click a ticker to view its fair-value analysis.
Dividend History
17 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹64.00/sh
Last payout
2026-02-05
₹11.00
Peak payout
₹11.00
Trailing yield
0.98%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Sun Pharmaceutical Industries (SUNPHARMA.NS) trades at 1680.10 vs a model fair value of 1349.88, a gap of -19.7%. Piotroski F-score: 6/9....
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SUNPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SUNPHARMA →
Compare
Head-to-head with peers
Compare SUNPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SUNPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.